Kahn Swick & Foti, LLC is investigating Humacyte, Inc. following the FDA's inspection that revealed serious violations at Humacyte's manufacturing facility, including lack of microbial quality assurance and testing. The FDA delayed approval of Humacyte's Biologic License Application for its acellular tissue engineered vessel product. Additionally, a securities class action lawsuit accusing the company and its executives of failing to disclose material information is moving forward after a court denied part of the company's dismissal motion. The investigation focuses on potential breaches of fiduciary duty and legal violations by Humacyte's officers and directors.
KORU Medical Systems is evolving into a digitally enabled drug delivery platform, benefiting from growth in at-home subcutaneous infusion therapies. The company reported an 18.2% increase in Q2 revenue to $12.05 million, with improved net income and ...
Ethereum wallets holding over 1000 ETH reduced their holdings by 2.9% from May to August, trimming 1.7 million coins. Meanwhile, smaller wallets holding 1 to 10 ETH increased their share, indicating retail accumulation. Staked ETH also rose to a reco...
Venice Token (VVV) has surged 11% in 24 hours following a breakout from its consolidation pattern, with the $21 pennant pole as the next key target. This rally is supported by Veil’s Multi-Asset Pool launch on Base, which includes VVV among its suppo...
The final significant IPO of August was priced this week, accompanied by a direct listing and two SPAC offerings. Defense technology company Lyntris priced its downsized IPO below the expected range. The IPO market is expected to remain quiet next we...
Canada halted trade negotiations with the US, citing unfair last-minute changes to the proposed terms. This decision came as the US prepared to impose 50% tariffs on $28 billion of Canadian goods. Canada responded by matching these tariffs and plans ...
